Biomea Fusion Inc BMEA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/29/24 EDT
10.75UNCH (UNCH)
Volume
6,524
Close
10.75UNCH (UNCH)
Volume
505,578
52 week range
8.12 - 43.69
Loading...
  • Open10.86
  • Day High11.16
  • Day Low10.61
  • Prev Close10.75
  • 52 Week High43.69
  • 52 Week High Date06/08/23
  • 52 Week Low8.12
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap385.811M
  • Shares Out35.89M
  • 10 Day Average Volume0.84M
  • Dividend-
  • Dividend Yield-
  • Beta-0.54
  • YTD % Change-25.96

KEY STATS

  • Open10.86
  • Day High11.16
  • Day Low10.61
  • Prev Close10.75
  • 52 Week High43.69
  • 52 Week High Date06/08/23
  • 52 Week Low8.12
  • 52 Week Low Date11/13/23
  • Market Cap385.811M
  • Shares Out35.89M
  • 10 Day Average Volume0.84M
  • Dividend-
  • Dividend Yield-
  • Beta-0.54
  • YTD % Change-25.96

RATIOS/PROFITABILITY

  • EPS (TTM)-3.46
  • P/E (TTM)-3.11
  • Fwd P/E (NTM)-2.72
  • EBITDA (TTM)-124.62M
  • ROE (TTM)-84.42%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/04/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Biomea Fusion Inc

 

Profile

MORE
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines...
Thomas Butler
Chairman of the Board, Chief Executive Officer, Co-Founder
Rainer Erdtmann
President, Co-Founder, Chief Operating Officer, Director
Franco Valle
Chief Financial Officer
Address
900 Middlefield Road, 4Th Floor
Redwood City, CA
94063
United States

Top Peers

SYMBOLLASTCHG%CHG
PEPG
PepGen Inc
11.68UNCHUNCH
REPL
Replimune Group Inc
6.58UNCHUNCH
LXRX
Lexicon Pharmaceuticals Inc
1.56UNCHUNCH
TRML
Tourmaline Bio Inc
15.50UNCHUNCH
LRMR
Larimar Therapeutics Inc
6.61UNCHUNCH